Introduction: Excessive daytime sleepiness (EDS) and fatigue have increased during the COVID-19 pandemic. The Second survey of the International COVID Sleep Study (ICOSS) includes data from 16 countries. Here we study effects of COVID-19 to EDS and fatigue. Method: Altogether, 15,859 persons participated. We included only those 11,996 (75.6%), who responded to all questions used in the analyses. The data were weighted by country using distributions of gender and age. Different questions have been described earlier in the ICOSS publications. Frequency of EDS and fatigue was asked as in the BNSQ. We used a cut point of ≥3 days/week to define significant EDS and fatigue. Results: The mean age was 43.0 years (SD 16.7). 31.7% were men and 68.3% women. 2231 (18.6%) had had a test positive COVID-19. Before the pandemic, 13.1% of all had EDS and 12.9% had fatigue. Later, in 2022, EDS was present in 22.1%, 34.9%, 49.0% and 58.7% in controls, those with mild COVID-19, moderate COVID-19, and severe/life threatening COVID-19, respectively. Fatigue was present in 22.2%, 37.8%, 51.1% and 64.2%, respectively in the same groups of severity as above. During a mild infection 65.5% reported EDS and 71.0% reported fatigue. During a severe infection 88.8% reported EDS and 79.3% reported fatigue. The ORs (stratified by age and gender) for EDS in 2022 were 1.74 (95% CI 1.52–2.0) for mild, 3.26 (2.74–3.87) for moderate, and 5.47 (4.03–7.42) for severe/life threating COVID-19. The OR of EDS for women was 1.35 (1.23–1.49). The OR of EDS was highest in the age-group 18–29 (OR 1.88 [1.54– 2.29]) (reference ≥70 y). The increase by decreasing age was almost linear. For fatigue, the ORs were 1.86 (1.64–2.11) for mild, 3.39 (2.85–4.04) for moderate, and 7.20 (5.24–9.88) for severe/ life threatening COVID-19. The OR of fatigue for women was 1.76 (1.60–1.94). The OR of fatigue increased almost linearly by decreasing age (ref ≥ 70). Conclusion: EDS and fatigue were very common after COVID-19 especially in the relatively younger groups and women. Occurrence of EDS and fatigue increased by severity of COVID-19. EDS and fatigue increased during the pandemic also in subjects who had not been infected.
Effect of COVID-19 pandemic on complaints of excessive daytime sleepiness and fatigue– ICOSS Consortium / Partinen, Eemil; Sarkanen, Tomi; Kwok Wing, Yun; Bjorvatn, Bjørn; Chung, Frances; DE GENNARO, Luigi; Holzinger, Brigitte; Merikanto, Ilona; Morin, Charles; Penzel, Thomas; Espie, Colin; Koscec Bjelajac, Adrijana; Ngan Yin Chan, Rachel; Suely Cunha, Ana; Benedict, Christian; Hrubos-Strøm, Harald; Inoue, Yuichi; Landtblom, Anne-Marie; Korman, Maria; Matsui, Kentaro; Mota-Rolim, Sergio; Nadorff, Michael; Plazzi, Giuseppe; Reis, Cátia; Yordanova, Juliana; Dauvilliers, Yves; Partinen, Markku. - In: JOURNAL OF SLEEP RESEARCH. - ISSN 0962-1105. - 33:S1(2024). [10.1111/jsr.14291]
Effect of COVID-19 pandemic on complaints of excessive daytime sleepiness and fatigue– ICOSS Consortium
Luigi De Gennaro;
2024
Abstract
Introduction: Excessive daytime sleepiness (EDS) and fatigue have increased during the COVID-19 pandemic. The Second survey of the International COVID Sleep Study (ICOSS) includes data from 16 countries. Here we study effects of COVID-19 to EDS and fatigue. Method: Altogether, 15,859 persons participated. We included only those 11,996 (75.6%), who responded to all questions used in the analyses. The data were weighted by country using distributions of gender and age. Different questions have been described earlier in the ICOSS publications. Frequency of EDS and fatigue was asked as in the BNSQ. We used a cut point of ≥3 days/week to define significant EDS and fatigue. Results: The mean age was 43.0 years (SD 16.7). 31.7% were men and 68.3% women. 2231 (18.6%) had had a test positive COVID-19. Before the pandemic, 13.1% of all had EDS and 12.9% had fatigue. Later, in 2022, EDS was present in 22.1%, 34.9%, 49.0% and 58.7% in controls, those with mild COVID-19, moderate COVID-19, and severe/life threatening COVID-19, respectively. Fatigue was present in 22.2%, 37.8%, 51.1% and 64.2%, respectively in the same groups of severity as above. During a mild infection 65.5% reported EDS and 71.0% reported fatigue. During a severe infection 88.8% reported EDS and 79.3% reported fatigue. The ORs (stratified by age and gender) for EDS in 2022 were 1.74 (95% CI 1.52–2.0) for mild, 3.26 (2.74–3.87) for moderate, and 5.47 (4.03–7.42) for severe/life threating COVID-19. The OR of EDS for women was 1.35 (1.23–1.49). The OR of EDS was highest in the age-group 18–29 (OR 1.88 [1.54– 2.29]) (reference ≥70 y). The increase by decreasing age was almost linear. For fatigue, the ORs were 1.86 (1.64–2.11) for mild, 3.39 (2.85–4.04) for moderate, and 7.20 (5.24–9.88) for severe/ life threatening COVID-19. The OR of fatigue for women was 1.76 (1.60–1.94). The OR of fatigue increased almost linearly by decreasing age (ref ≥ 70). Conclusion: EDS and fatigue were very common after COVID-19 especially in the relatively younger groups and women. Occurrence of EDS and fatigue increased by severity of COVID-19. EDS and fatigue increased during the pandemic also in subjects who had not been infected.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
